View in EDS HTML Full Text PDF Full Text

Cost-utility analysis of teriflunomide in naïve vs. previously treated patients with relapsing-remitting multiple sclerosis in Italy.

Saved in:
Bibliographic Details
Title: Cost-utility analysis of teriflunomide in naïve vs. previously treated patients with relapsing-remitting multiple sclerosis in Italy.
Authors: Lazzaro, Carlo (AUTHOR), Bergamaschi, Roberto (AUTHOR), Zaffaroni, Mauro (AUTHOR), Totaro, Rocco (AUTHOR), Paolicelli, Damiano (AUTHOR)
Source: Neurological Sciences. Aug2022, Vol. 43 Issue 8, p4933-4944. 12p. 3 Charts, 4 Graphs.
Subjects: Multiple sclerosis, Organic compounds, Cost benefit analysis, Immunosuppressive agents, Probability theory, Butyric acid, Croton oil, Hydroxy acids
Abstract: Background: Multiple sclerosis (MS) accounts for 176 cases per 100,000 inhabitants (female/male ratio = 2:1) in Italy. For most of the patients (67%), the disease course is relapsing-remitting MS (RRMS).Objective: To compare the costs and quality-adjusted life years (QALYs) of teriflunomide in RRMS naïve patients vs. RRMS patients previously treated (experienced) with other disease-modifying therapies in Italy.Methods: A four health states Markov model-supported cost-utility analysis (CUA) covering a 7-year timespan through annual cycles was developed, following the healthcare sector and the societal viewpoints. Part of the parameters that populated the Markov model was obtained from a questionnaire administered to four primary Italian MS centres. Costs of healthcare and non-healthcare resources, expressed in euro (€) 2019, and QALYs were discounted at 3% real social discount rate. One-way, scenario and probabilistic sensitivity analyses tested the uncertainty of the baseline findings.Results: Baseline CUA shows that teriflunomide in RRMS naïve patients is strongly dominant vs. experienced patients (healthcare sector perspective: - €1042.68 and + 0.480 QALYs; societal perspective: - €6782.81 and + 0.480 QALYs). Sensitivity analyses confirmed the robustness of the baseline results.Conclusion: Teriflunomide in RRMS naïve vs. experienced patients is cost-effective and possibly strongly dominant from both the healthcare sector and the society viewpoints in Italy. Our findings need further confirmation from real-world studies. [ABSTRACT FROM AUTHOR]
Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 158336182
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Cost-utility analysis of teriflunomide in naïve vs. previously treated patients with relapsing-remitting multiple sclerosis in Italy.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Lazzaro%2C+Carlo%22">Lazzaro, Carlo</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bergamaschi%2C+Roberto%22">Bergamaschi, Roberto</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zaffaroni%2C+Mauro%22">Zaffaroni, Mauro</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Totaro%2C+Rocco%22">Totaro, Rocco</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Paolicelli%2C+Damiano%22">Paolicelli, Damiano</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Neurological+Sciences%22">Neurological Sciences</searchLink>. Aug2022, Vol. 43 Issue 8, p4933-4944. 12p. 3 Charts, 4 Graphs.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Multiple+sclerosis%22">Multiple sclerosis</searchLink><br /><searchLink fieldCode="DE" term="%22Organic+compounds%22">Organic compounds</searchLink><br /><searchLink fieldCode="DE" term="%22Cost+benefit+analysis%22">Cost benefit analysis</searchLink><br /><searchLink fieldCode="DE" term="%22Immunosuppressive+agents%22">Immunosuppressive agents</searchLink><br /><searchLink fieldCode="DE" term="%22Probability+theory%22">Probability theory</searchLink><br /><searchLink fieldCode="DE" term="%22Butyric+acid%22">Butyric acid</searchLink><br /><searchLink fieldCode="DE" term="%22Croton+oil%22">Croton oil</searchLink><br /><searchLink fieldCode="DE" term="%22Hydroxy+acids%22">Hydroxy acids</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: <bold>Background: </bold>Multiple sclerosis (MS) accounts for 176 cases per 100,000 inhabitants (female/male ratio = 2:1) in Italy. For most of the patients (67%), the disease course is relapsing-remitting MS (RRMS).<bold>Objective: </bold>To compare the costs and quality-adjusted life years (QALYs) of teriflunomide in RRMS naïve patients vs. RRMS patients previously treated (experienced) with other disease-modifying therapies in Italy.<bold>Methods: </bold>A four health states Markov model-supported cost-utility analysis (CUA) covering a 7-year timespan through annual cycles was developed, following the healthcare sector and the societal viewpoints. Part of the parameters that populated the Markov model was obtained from a questionnaire administered to four primary Italian MS centres. Costs of healthcare and non-healthcare resources, expressed in euro (€) 2019, and QALYs were discounted at 3% real social discount rate. One-way, scenario and probabilistic sensitivity analyses tested the uncertainty of the baseline findings.<bold>Results: </bold>Baseline CUA shows that teriflunomide in RRMS naïve patients is strongly dominant vs. experienced patients (healthcare sector perspective: - €1042.68 and + 0.480 QALYs; societal perspective: - €6782.81 and + 0.480 QALYs). Sensitivity analyses confirmed the robustness of the baseline results.<bold>Conclusion: </bold>Teriflunomide in RRMS naïve vs. experienced patients is cost-effective and possibly strongly dominant from both the healthcare sector and the society viewpoints in Italy. Our findings need further confirmation from real-world studies. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=158336182
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10072-022-06022-x
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 12
        StartPage: 4933
    Subjects:
      – SubjectFull: Multiple sclerosis
        Type: general
      – SubjectFull: Organic compounds
        Type: general
      – SubjectFull: Cost benefit analysis
        Type: general
      – SubjectFull: Immunosuppressive agents
        Type: general
      – SubjectFull: Probability theory
        Type: general
      – SubjectFull: Butyric acid
        Type: general
      – SubjectFull: Croton oil
        Type: general
      – SubjectFull: Hydroxy acids
        Type: general
    Titles:
      – TitleFull: Cost-utility analysis of teriflunomide in naïve vs. previously treated patients with relapsing-remitting multiple sclerosis in Italy.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lazzaro, Carlo
      – PersonEntity:
          Name:
            NameFull: Bergamaschi, Roberto
      – PersonEntity:
          Name:
            NameFull: Zaffaroni, Mauro
      – PersonEntity:
          Name:
            NameFull: Totaro, Rocco
      – PersonEntity:
          Name:
            NameFull: Paolicelli, Damiano
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: Aug2022
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 15901874
          Numbering:
            – Type: volume
              Value: 43
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: Neurological Sciences
              Type: main
ResultId 1